Literature DB >> 35880530

Predictive Utility of a Validated Polygenic Risk Score for Long-Term Risk of Coronary Heart Disease in Young and Middle-Aged Adults.

Sadiya S Khan1,2, Courtney Page3, Daniel M Wojdyla3, Yosef Y Schwartz4, Philip Greenland1, Michael J Pencina3.   

Abstract

BACKGROUND: Understanding the predictive utility of previously derived polygenic risk scores (PRSs) for long-term risk of coronary heart disease (CHD) and its additive value beyond traditional risk factors can inform prevention strategies.
METHODS: Data from adults 20 to 59 years of age who were free of CHD from the FOS (Framingham Offspring Study) and the ARIC (Atherosclerosis Risk in Communities) study were analyzed. Because the PRS was derived from samples of predominantly European ancestry, individuals who self-reported White race were included. The sample was stratified by age and cohort: young (FOS, 20-39 years [median, 30 years] of age), early midlife (FOS, 40-59 years [median, 43] years of age), and late midlife (ARIC, 45-59 years [median, 52 years] of age). Two previously derived and validated prediction tools were applied: (1) a 30-year traditional risk factor score and (2) a genome-wide PRS comprising >6 million genetic variants. Hazard ratios for the association between each risk estimate and incident CHD were calculated. Predicted and observed rates of CHD were compared to assess discrimination for each model individually and together with the optimism-corrected C index (95% CI).
RESULTS: Among 9757 participants, both the traditional risk factor score (hazard ratio per 1 SD, 2.60 [95% CI, 2.08-3.27], 2.09 [95% CI, 1.83-2.40], and 2.11 [95% CI, 1.96-2.28]) and the PRS (hazard ratio, 1.98 [95% CI, 1.70-2.30], 1.64 [95% CI, 1.47-1.84], and 1.22 [95% CI, 1.15-1.30]) were significantly associated with incident CHD in young, early midlife, and late midlife, respectively. Discrimination was similar or better for the traditional risk factor score (C index, 0.74 [95% CI, 0.70-0.78], 0.70 [95% CI, 0.67-0.72], and 0.72 [95% CI, 0.70-0.73]) compared with an age- and sex-adjusted PRS (0.73 [95% CI, 0.69-0.78], 0.66 [95% CI, 0.62-0.69], and 0.66 [95% CI, 0.64-0.67]) in young, early-midlife, and late-midlife participants, respectively. The ΔC index when PRS was added to the traditional risk factor score was 0.03 (95% CI, 0.001-0.05), 0.02 (95% CI, -0.002 to 0.037), and 0.002 (95% CI, -0.002 to 0.006) in young, early-midlife, and late-midlife participants, respectively.
CONCLUSIONS: Despite a statistically significant association between PRS and 30-year risk of CHD, the C statistic improved only marginally with the addition of PRS to the traditional risk factor model among young adults and did not improve among midlife adults. PRS, an immutable factor that cannot be directly intervened on, has minimal clinical utility for long-term CHD prediction when added to a traditional risk factor model.

Entities:  

Keywords:  coronary artery disease; genetic predisposition to disease; risk assessment; risk factors

Mesh:

Year:  2022        PMID: 35880530      PMCID: PMC9398962          DOI: 10.1161/CIRCULATIONAHA.121.058426

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   39.918


  47 in total

1.  The path to personalized medicine.

Authors:  Margaret A Hamburg; Francis S Collins
Journal:  N Engl J Med       Date:  2010-06-15       Impact factor: 91.245

2.  Principal components analysis corrects for stratification in genome-wide association studies.

Authors:  Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich
Journal:  Nat Genet       Date:  2006-07-23       Impact factor: 38.330

3.  Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.

Authors:  Amy Damask; P Gabriel Steg; Gregory G Schwartz; Michael Szarek; Emil Hagström; Lina Badimon; M John Chapman; Catherine Boileau; Sotirios Tsimikas; Henry N Ginsberg; Poulabi Banerjee; Garen Manvelian; Robert Pordy; Sibylle Hess; John D Overton; Luca A Lotta; George D Yancopoulos; Goncalo R Abecasis; Aris Baras; Charles Paulding
Journal:  Circulation       Date:  2019-11-11       Impact factor: 29.690

4.  Interpreting incremental value of markers added to risk prediction models.

Authors:  Michael J Pencina; Ralph B D'Agostino; Karol M Pencina; A Cecile J W Janssens; Philip Greenland
Journal:  Am J Epidemiol       Date:  2012-08-08       Impact factor: 4.897

5.  A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.

Authors:  George Thanassoulis; Allan D Sniderman; Michael J Pencina
Journal:  JAMA Cardiol       Date:  2018-11-01       Impact factor: 14.676

6.  Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance. The Framingham Offspring Study.

Authors:  J B Meigs; D M Nathan; P W Wilson; L A Cupples; D E Singer
Journal:  Ann Intern Med       Date:  1998-04-01       Impact factor: 25.391

7.  An investigation of coronary heart disease in families. The Framingham offspring study.

Authors:  W B Kannel; M Feinleib; P M McNamara; R J Garrison; W P Castelli
Journal:  Am J Epidemiol       Date:  1979-09       Impact factor: 4.897

Review 8.  The ARIC (Atherosclerosis Risk In Communities) Study: JACC Focus Seminar 3/8.

Authors:  Jacqueline D Wright; Aaron R Folsom; Josef Coresh; A Richey Sharrett; David Couper; Lynne E Wagenknecht; Thomas H Mosley; Christie M Ballantyne; Eric A Boerwinkle; Wayne D Rosamond; Gerardo Heiss
Journal:  J Am Coll Cardiol       Date:  2021-06-15       Impact factor: 27.203

9.  Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention.

Authors:  Michael Inouye; Gad Abraham; Christopher P Nelson; Angela M Wood; Michael J Sweeting; Frank Dudbridge; Florence Y Lai; Stephen Kaptoge; Marta Brozynska; Tingting Wang; Shu Ye; Thomas R Webb; Martin K Rutter; Ioanna Tzoulaki; Riyaz S Patel; Ruth J F Loos; Bernard Keavney; Harry Hemingway; John Thompson; Hugh Watkins; Panos Deloukas; Emanuele Di Angelantonio; Adam S Butterworth; John Danesh; Nilesh J Samani
Journal:  J Am Coll Cardiol       Date:  2018-10-16       Impact factor: 24.094

10.  US life expectancy stalls due to cardiovascular disease, not drug deaths.

Authors:  Neil K Mehta; Leah R Abrams; Mikko Myrskylä
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.